Product nameAnti-Paxillin antibody
See all Paxillin primary antibodies
DescriptionRabbit polyclonal to Paxillin
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Chicken, Xenopus laevis
Synthetic peptide within Human Paxillin (internal sequence). The exact sequence is proprietary. Carrier-protein conjugated
Database link: P49023
- WB: A431 whole cell extract treated with 100nM Calyculin A for 30 minutes.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.025% Proclin
Constituents: PBS, 1% BSA, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab229773 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 65 kDa.|
FunctionCytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion).
Sequence similaritiesBelongs to the paxillin family.
Contains 4 LIM zinc-binding domains.
modificationsPhosphorylated on tyrosine residues during integrin-mediated cell adhesion, embryonic development, fibroblast transformation and following stimulation of cells by mitogens.
Cellular localizationCytoplasm > cytoskeleton. Cell junction > focal adhesion.
- Information by UniProt
- FLJ16691 antibody
- FLJ23042 antibody
- Paired box protein Pax 1 antibody
All lanes : Anti-Paxillin antibody (ab229773) at 1/3000 dilution
Lane 1 : A431 (human epidermoid carcinoma cell line) whole cell extract
Lane 2 : A431 (human epidermoid carcinoma cell line) treated with 100nM of Calyculin A for 30 minutes, whole cell extract
Lysates/proteins at 30 µg per lane.
Predicted band size: 65 kDa
7.5% SDS-PAGE gel.
ab229773 has not yet been referenced specifically in any publications.